– SWITZERLAND, Geneva – ObsEva SA (SIX: OBSN |NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the nomination of Anne VanLent for her election to its Board of Directors at the 2021 AGM to be held on May 28, 2021. Anne VanLent will replace Barbara Duncan, who will not stand for re-election at the Board of Directors.
About Anne VanLent
Anne VanLent is a seasoned senior life sciences executive with over 35 years of management and governance experience with emerging growth companies. Since 2008, Anne has provided strategic, financial, and management consulting services to emerging growth companies in the life sciences and technology arenas through her consulting company AMV Advisors. Assignments have included strategic financial funding and structuring advice, mergers and acquisitions transaction support, and interim Chief Financial Officer services. She has been a member of the board of directors of at least one public company consistently for over twenty years, serving 10 different medical device and biopharmaceutical public companies. She currently serves as a member of the board of directors and audit committee chair for Applied Genetics Technologies Corporation (NASDAQ: AGTC) and Trevi Therapeutics, Inc. (NASDAQ: TRVI).
Before 2008, Anne was EVP and CFO for Barrier Therapeutics, Inc., a Johnson & Johnson spin-off company focused on dermatology which she helped take public in 2004. She had previously served as EVP of Ventures and Licensing for the Sarnoff Corporation and as CFO for The Liposome Company, Inc., a publicly-traded specialty pharmaceutical company, and Neurogenics, Inc. a venture-backed biotechnology company focused on neurotrophic growth factors. She began her career in the food industry focused on operations, finance, and business line optimization.
Anne is active in the not-for-profit world through governance and philanthropy, with a focus on global health, women’s empowerment, and the arts. She has been on the board of IAVI (formerly the International AIDS Vaccine Initiative), a global nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis, since 2008 and currently serves as Vice-Chair. She is also a Trustee of McCarter Theatre and the Princeton Area Community Foundation and is a past trustee and current advisor to the Princeton Symphony Orchestra, the Arts Council of Princeton, and WIL in Philadelphia, PA.
Anne received a BA in Physics with high honors from Mount Holyoke College and studied biophysics as a Rotary Scholar at the Center for Macromolecular Research at the University of Strasbourg, France. She resides in Princeton, NJ, and Old Saybrook, CT.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”.
For more information: https://www.obseva.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.